Page last updated: 2024-10-27

fluorouracil and Cholangiocellular Carcinoma

fluorouracil has been researched along with Cholangiocellular Carcinoma in 163 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"Patients with gallbladder cancer or cholangiocarcinoma were treated with the combination of gemcitabine 1,000 mg/m(2) IV over 100 min on days 1 and 8 and capecitabine 650 mg/m(2) BID PO on days 1-14, administered every 21 days."9.15A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. ( Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C, 2011)
"Gemcitabine based regimens have been widely used in patients with advanced cholangiocarcinoma (CC), but no standard therapy exists."9.15A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. ( Jakobsen, A; Jensen, LH; Lassen, U; Rohrberg, KS; Sorensen, M; Ujmajuridze, Z, 2011)
"5-Fluorouracil (5-FU), a thymidylate synthase (TS) inhibitor, has been used as the first-line chemotherapeutic drug for cholangiocarcinoma (CCA)."8.02FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. ( Klinhom-On, N; Mahalapbutr, P; Obchoei, S; Sawanyawisuth, K; Seubwai, W; Wongkham, S, 2021)
"Gemcitabine plus platinum as the first-line chemotherapy for cholangiocarcinoma (CCA) has limited efficacy."8.02Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study. ( Cui, J; Cui, X; Gong, W; Han, X; Lau, WY; Li, H; Li, M; Li, X; Liu, Y; Ren, T; Song, X; Wang, L; Wang, X; Wu, W; Wu, X; Zhu, Y; Zou, L, 2021)
"Application of 5-fluorouracil (5-FU) in cholangiocarcinoma (CCA) is limited by adverse side effects and chemoresistance."8.02Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo. ( Jeeunngoi, J; Ketterman, AJ; Prompipak, J; Senawong, G; Senawong, T; Sripa, B; Utaiwat, S; Woranam, K, 2021)
"Fluorouracil (5-FU) is the first-line chemotherapeutic drug for cholangiocarcinoma (CCA), but its efficacy has been compromised by the development of resistance."7.88FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance. ( Intuyod, K; Jiramongkol, Y; Lai, CF; Lam, EW; Luvira, V; Pairojkul, C; Pinlaor, S; Saavedra-García, P; Trakansuebkul, S; Vaeteewoottacharn, K; Waraasawapati, S; Wongkham, S; Yao, S; Yong, JS; Zona, S, 2018)
"To establish and characterize the gemcitabine-resistant cholangiocarcinoma (CCA) cell lines, CCA KKU‑M139 and KKU‑M214 cell lines were exposed stepwisely to increasing gemcitabine (GEM)."7.81Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. ( Boonmars, T; Hahnvajanawong, C; Jearanaikoon, P; Kanchanawat, S; Leelayuwat, C; Namwat, N; Seubwai, W; Techasen, A; Wattanawongdon, W, 2015)
"The aim of the present study was to investigate the role of NK4, an antagonist for hepatocyte growth factor (HGF) and the Met receptor, in regulating the response of cholangiocarcinoma (CCA) cells to 5-fluorouracil (5-FU)."7.79NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway. ( Ge, X; Ji, G; Li, Q; Miao, L; Wang, Y; Yu, H, 2013)
"To determine whether expression of certain enzymes related to 5-fluorouracil (5-FU) metabolism predicts 5-FU chemosensitivity in cholangiocarcinoma (CCA)."7.78Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. ( Bhudhisawasdi, V; Chaiyagool, J; Hahnvajanawong, C; Khuntikeo, N; Namwat, N; Pugkhem, A; Seubwai, W; Sripa, B; Tassaneeyakul, W, 2012)
"Inhibition of TP may be beneficial in decreasing angiogenesis-dependent growth and migration of cholangiocarcinoma but may diminish the response to 5-fluorouracil chemotherapy."7.76Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. ( Jearanaikoon, P; Limpaiboon, T; Miwa, M; Pairojkul, C; Sripa, B; Tantimavanich, S; Thanasai, J, 2010)
"We assessed the effect of purified green tea catechins on chemotherapy-induced apoptosis in KMCH, CC-LP-1 and Mz-ChA-1 human cholangiocarcinoma cells, and on chemosensitivity of Mz-ChA-1 cell xenografts in nude mice."7.75Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. ( Braconi, C; Henson, R; Lang, M; Patel, T, 2009)
"We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy."7.74[A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008)
"Although 5-fluorouracil (5-FU) is the drug of choice for the palliative treatment of cholangiocarcinoma (CCA), resistance to the drug is a therapeutic obstacle."7.74Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines. ( Amimanan, P; Bhudhisawasdi, V; Jearanaikoon, P; Loilome, W; Namwat, N; Sripa, B; Tassaneeyakul, W, 2008)
"The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine."7.72Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004)
"Capecitabine could potentially be used for secondline treatment in patients with progressive metastatic cholangiocarcinoma."7.71Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases. ( Heinemann, V; Schalhorn, A; Stemmler, J, 2002)
"The adjuvant therapy (AT) for biliary tract cancer (BTC) patients after surgery has always been controversial."6.82The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis. ( Cheng, Q; Gong, S; Guo, T; Lei, C; Lu, T; Lv, K; Song, S; Tian, H; Yang, K; Yang, W, 2022)
"The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknown."6.80SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. ( Alberts, SR; Ben-Josef, E; Blanke, CD; Corless, CL; Dawson, LA; El-Khoueiry, AB; Guthrie, KA; Lowy, AM; Micetich, KC; Siegel, AB; Thomas, CR; Thomas, MB; Zalupski, MM, 2015)
"Bile duct cancer is characterized by fast metastasis and invasion and has been regarded as one of the most aggressive tumors due to the absence of effective diagnosis at an early stage."5.51Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells. ( Fan, QX; Guo, SS; Wang, Y, 2019)
"(Ham-1) cells both in vitro and in vivo."5.46Synergistic Effect of Forbesione From Garcinia hanburyi in Combination with 5-Fluorouracil on Cholangiocarcinoma ( Anantachoke, N; Boonmars, T; Boueroy, P; Hahnvajanawong, C; Kongsanthia, C; Reutrakul, V; Saensa-ard, S; Salao, K; Wattanawongdon, W; Wongwajana, S, 2017)
"There are limits to the standard treatment for cholangiocarcinoma (CCA) including drug resistance and side effects."5.43Targeted delivery of 5-fluorouracil to cholangiocarcinoma cells using folic acid as a targeting agent. ( Boonsiri, P; Daduang, J; Daduang, S; Limpaiboon, T; Ngernyuang, N; Seubwai, W, 2016)
"Cholangiocarcinoma is categorized into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC)."5.40Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma. ( Kasai, K; Kasai, Y; Kooka, Y; Miyamoto, Y; Oikawa, K; Oikawa, T; Sawara, K; Suzuki, A; Suzuki, Y; Takikawa, Y; Ushio, A, 2014)
" The treatment did not cause any serious adverse events, except hypercalcemia grade I, once in 72 administrations."5.38Evaluation of efficacy, safety and tolerability of high dose-intermittent calcitriol supplementation to advanced intrahepatic cholangiocarcinoma patients--a pilot study. ( Bhudhisawasdi, V; Chamadol, N; Chur-in, S; Janeklang, S; Khuntikeo, N; Kukongviriyapan, V; Pairojkul, C; Prawan, A; Pugkhem, A; Sookprasert, A; Vaeteewoottacharn, K; Wongkham, S, 2012)
"Capecitabine was administered orally at a dose of 1,000 mg/m(2) twice a day for 14 days, followed by a 1-week rest period."5.38Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. ( Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM, 2012)
" We determined the anticancer effects of VPA combined with 5-FU in these cell lines."5.37Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. ( Hanaoka, J; Ikemoto, T; Imura, S; Ishibashi, H; Iwahashi, S; Mori, H; Morine, Y; Ochir, TL; Shimada, M; Utsunomiya, T, 2011)
"Cholangiocarcinomas are devastating cancers that are resistant to chemotherapies."5.36Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents. ( DeMorrow, S; Frampton, GA; Lazcano, EA; Li, H; Mohamad, A, 2010)
" Cholangiocellular carcinoma cells (TFK-1 cells) were treated either with 8 Gy (RTB group) or 16 Gy (RTA group) (188)Re or with (188)Re irradiation (8 Gy) combined with either gemcitabine (8 Gy/Gem) or 5-fluorouracil (8 Gy/5-FU) at a dosage of 20 microg/ml medium for 4 days and subsequently compared with an untreated control group."5.35Impact of rhenium-188, gemcitabine, and 5-fluorouracil on cholangiocellular carcinoma cells: an in vitro study. ( Bantleon, R; Farkas, E; Kehlbach, R; Werner, M; Wiesinger, B; Wiskirchen, J, 2009)
"The MTD of (90)Y delivered in conjunction with capecitabine in the setting of intrahepatic cholangiocarcinoma or metastatic disease confined to the liver exceeds 170 Gy."5.19Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. ( Benson, AB; Gates, VL; Habib, A; Hickey, R; Kircher, S; Lewandowski, RJ; Mulcahy, MF; Newman, S; Nimeiri, H; Salem, R; Vouche, M, 2014)
"Gemcitabine based regimens have been widely used in patients with advanced cholangiocarcinoma (CC), but no standard therapy exists."5.15A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. ( Jakobsen, A; Jensen, LH; Lassen, U; Rohrberg, KS; Sorensen, M; Ujmajuridze, Z, 2011)
"Patients with gallbladder cancer or cholangiocarcinoma were treated with the combination of gemcitabine 1,000 mg/m(2) IV over 100 min on days 1 and 8 and capecitabine 650 mg/m(2) BID PO on days 1-14, administered every 21 days."5.15A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. ( Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C, 2011)
" The authors evaluated 6-month survival, response, and toxicity associated with a combination of gemcitabine, 5-fluorouracil (5-FU), and leucovorin (LV) in patients with unresectable or metastatic biliary tract or gallbladder adenocarcinoma (ACA)."5.11Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. ( Al-Khatib, H; Alberts, SR; Burgart, L; Cera, PJ; Finch, TR; Flynn, PJ; Knost, JA; Levitt, R; Mahoney, MR; Tschetter, LK; Windschitl, HE, 2005)
"We have reported a 33% partial response rate with acceptable toxicity using weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with far advanced biliary tract cancers (BTC)."5.09Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. ( Chen, JS; Jan, YY; Liau, CT; Lin, YC, 2001)
" We aim to explore the roles of LncFALEC and miR-20a-5p/SHOC2 axis on the proliferation, migration, and Fluorouracil (5-FU) resistance of cholangiocarcinoma (CCA)."4.31LncRNA FALEC increases the proliferation, migration and drug resistance of cholangiocarcinoma through competitive regulation of miR-20a-5p/SHOC2 axis. ( Du, H; Hou, S; Liu, C; Yu, T; Zhang, L; Zhang, W, 2023)
"Application of 5-fluorouracil (5-FU) in cholangiocarcinoma (CCA) is limited by adverse side effects and chemoresistance."4.02Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo. ( Jeeunngoi, J; Ketterman, AJ; Prompipak, J; Senawong, G; Senawong, T; Sripa, B; Utaiwat, S; Woranam, K, 2021)
"5-Fluorouracil (5-FU), a thymidylate synthase (TS) inhibitor, has been used as the first-line chemotherapeutic drug for cholangiocarcinoma (CCA)."4.02FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. ( Klinhom-On, N; Mahalapbutr, P; Obchoei, S; Sawanyawisuth, K; Seubwai, W; Wongkham, S, 2021)
"Gemcitabine plus platinum as the first-line chemotherapy for cholangiocarcinoma (CCA) has limited efficacy."4.02Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study. ( Cui, J; Cui, X; Gong, W; Han, X; Lau, WY; Li, H; Li, M; Li, X; Liu, Y; Ren, T; Song, X; Wang, L; Wang, X; Wu, W; Wu, X; Zhu, Y; Zou, L, 2021)
"Fluorouracil (5-FU) is the first-line chemotherapeutic drug for cholangiocarcinoma (CCA), but its efficacy has been compromised by the development of resistance."3.88FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance. ( Intuyod, K; Jiramongkol, Y; Lai, CF; Lam, EW; Luvira, V; Pairojkul, C; Pinlaor, S; Saavedra-García, P; Trakansuebkul, S; Vaeteewoottacharn, K; Waraasawapati, S; Wongkham, S; Yao, S; Yong, JS; Zona, S, 2018)
"Thirteen consecutive patients with metastatic intrahepatic cholangiocarcinoma who were refractory to first-line therapy consisting of gemcitabine plus oxaliplatin-based first-line chemotherapy given intravenously via intra-arterial infusion were treated with FOLFIRI [irinotecan (180 mg/m² i."3.81FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. ( Bengrine, L; Ghiringhelli, F; Guion-Dusserre, JF; Lorgis, V; Vincent, J, 2015)
"To establish and characterize the gemcitabine-resistant cholangiocarcinoma (CCA) cell lines, CCA KKU‑M139 and KKU‑M214 cell lines were exposed stepwisely to increasing gemcitabine (GEM)."3.81Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. ( Boonmars, T; Hahnvajanawong, C; Jearanaikoon, P; Kanchanawat, S; Leelayuwat, C; Namwat, N; Seubwai, W; Techasen, A; Wattanawongdon, W, 2015)
" Green fluorescent protein-labeled human cholangiocarcinoma cells and cholangiocarcinomas in 24 mice were treated with (a) combination therapy with chemotherapy (gemcitabine and 5-FU) plus RF hyperthermia, (b) chemotherapy only, (c) RF hyperthermia only, or (d) phosphate-buffered saline."3.80Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging--preclinical study. ( Kolokythas, O; Le, T; Meng, Y; Soriano, SS; Wang, H; Wei, B; Willis, P; Wu, X; Yang, X; Zhang, F; Zhang, T, 2014)
"Tumor control and survival of patient with advanced cholangiocarcinoma treated with gemcitabine-based and 5FU-based chemotherapy do not markedly differ."3.79Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand. ( Butthongkomvong, K; Jhankumpha, S; Kumdang, S; Sirachainan, E; Sukhontharot, OU, 2013)
"The aim of the present study was to investigate the role of NK4, an antagonist for hepatocyte growth factor (HGF) and the Met receptor, in regulating the response of cholangiocarcinoma (CCA) cells to 5-fluorouracil (5-FU)."3.79NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway. ( Ge, X; Ji, G; Li, Q; Miao, L; Wang, Y; Yu, H, 2013)
"To determine whether expression of certain enzymes related to 5-fluorouracil (5-FU) metabolism predicts 5-FU chemosensitivity in cholangiocarcinoma (CCA)."3.78Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. ( Bhudhisawasdi, V; Chaiyagool, J; Hahnvajanawong, C; Khuntikeo, N; Namwat, N; Pugkhem, A; Seubwai, W; Sripa, B; Tassaneeyakul, W, 2012)
"Cytotoxic activity of artemisinin and derivatives in the presence and absence of holo-transferrin and expression of genes involved in resistance of cancer cells were investigated in human cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines in vitro."3.77Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines. ( Chaijaroenkul, W; Mahavorasirikul, W; Na-Bangchang, K; Viyanant, V, 2011)
"Inhibition of TP may be beneficial in decreasing angiogenesis-dependent growth and migration of cholangiocarcinoma but may diminish the response to 5-fluorouracil chemotherapy."3.76Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. ( Jearanaikoon, P; Limpaiboon, T; Miwa, M; Pairojkul, C; Sripa, B; Tantimavanich, S; Thanasai, J, 2010)
" We evaluated the effects of these adenoviruses with 5-fluorouracil (5-FU) and/or ganciclovir (GCV) on human cholangiocarcinoma cells (HuCCT1, with mutant p53) in vitro and in vivo."3.75Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models. ( Hamada, H; Honda, K; Kobayashi, N; Kojima, Y, 2009)
"We assessed the effect of purified green tea catechins on chemotherapy-induced apoptosis in KMCH, CC-LP-1 and Mz-ChA-1 human cholangiocarcinoma cells, and on chemosensitivity of Mz-ChA-1 cell xenografts in nude mice."3.75Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells. ( Braconi, C; Henson, R; Lang, M; Patel, T, 2009)
"We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy."3.74[A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008)
"Although 5-fluorouracil (5-FU) is the drug of choice for the palliative treatment of cholangiocarcinoma (CCA), resistance to the drug is a therapeutic obstacle."3.74Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines. ( Amimanan, P; Bhudhisawasdi, V; Jearanaikoon, P; Loilome, W; Namwat, N; Sripa, B; Tassaneeyakul, W, 2008)
"The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine."3.72Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004)
"Capecitabine could potentially be used for secondline treatment in patients with progressive metastatic cholangiocarcinoma."3.71Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases. ( Heinemann, V; Schalhorn, A; Stemmler, J, 2002)
"Cholangiocarcinoma is a deadly cancer comprising very heterogenous subtypes with a limited therapeutic arsenal in all comers."3.01Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ? ( Edeline, J; Lièvre, A; Malka, D; Neuzillet, C; Roth, GS; Sarabi, M, 2023)
"The adjuvant therapy (AT) for biliary tract cancer (BTC) patients after surgery has always been controversial."2.82The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis. ( Cheng, Q; Gong, S; Guo, T; Lei, C; Lu, T; Lv, K; Song, S; Tian, H; Yang, K; Yang, W, 2022)
"The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknown."2.80SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. ( Alberts, SR; Ben-Josef, E; Blanke, CD; Corless, CL; Dawson, LA; El-Khoueiry, AB; Guthrie, KA; Lowy, AM; Micetich, KC; Siegel, AB; Thomas, CR; Thomas, MB; Zalupski, MM, 2015)
"Intrahepatic cholangiocellular carcinoma after curative surgery was treated with pharmacokinetic modulation chemotherapy (PMC) as adjuvant chemotherapy."2.74[Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma]. ( Fukumori, D; Kamachi, H; Kamiyama, T; Matsushita, M; Nakagawa, T; Nakanishi, K; Tahara, M; Todo, S; Yokoo, H, 2009)
"Our results show that the regimen of gemcitabine combined with capecitabine is effective and well tolerated in patients with unresectable relapsed or metastatic carcinoma of the biliary tract."2.73[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma]. ( Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY, 2008)
"Cholangiocarcinoma is a rare malignancy with a poor prognosis."2.72Biliary cancer: gateway to comprehensive molecular profiling. ( Sardar, M; Shroff, RT, 2021)
"Mitomycin C (MMC) in combination with infusional 5-fluorouracil (FU) plus folinic acid (FA) is an effective treatment for metastatic gastrointestinal cancer."2.71Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer. ( Gnad, U; Hartmann, JT; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Saussele, S; Weisser, A; Willer, A, 2004)
"The term of biliary tract cancer (BTC) refers to all tumors that arise from the biliary tract or the biliary drainage system, including the intra- and extra-hepatic bile ducts as well as the gallbladder."2.55[Chemotherapy for Biliary Tract Cancer]. ( Woo, SM, 2017)
"Most patients with intrahepatic cholangiocarcinoma (IH-CCA) are unresectable and treatment options are limited."2.52Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience. ( Bassi, N; Bonariol, L; Bonariol, R; Caratozzolo, E; Massani, M; Morana, G; Nistri, C; Pauletti, B; Ruffolo, C, 2015)
"Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug."2.45The role of capecitabine in the management of tumors of the digestive system. ( Gennatas, C; Gennatas, S; Michalaki, V, 2009)
"Cholangiocarcinoma is a rare malignancy arising from the bile duct epithelium with a grim prognosis."2.45Role of liver transplantation in the treatment of cholangiocarcinoma. ( Marrero, JA; Singal, A; Welling, TH, 2009)
"Other costs related to advanced intrahepatic cholangiocarcinoma were calculated using National Health Insurance claims data."1.91Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. ( Chen, ZR; Chiang, NJ; Chueh, CH; Shiu, MN; Tsai, YW; Wen, YW, 2023)
"Our results provide preliminary evidence that HAIC based on FOLFIRI regimen is efficient and safe in some patients progressing after previous treatment."1.72The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study. ( Chen, Y; Huang, P; Huang, X; Shi, G; Sun, Q; Yang, G; Zhou, Y, 2022)
"Cholangiocarcinoma is the first most common cancer of the biliary tract."1.62In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells. ( Cavaletti, G; Celio, L; Damian, S; Malacrida, A; Mazzaferro, V; Miloso, M; Rigolio, R, 2021)
"Huaier combined with 5-FU exhibited a synergistic anti-tumor effect in Huh28 cell."1.51The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells. ( Che, C; Dong, B; Dong, C; Fu, Z; Liang, R; Ma, K; Wang, H; Wang, X; Zhang, R; Zhao, C, 2019)
"Bile duct cancer is characterized by fast metastasis and invasion and has been regarded as one of the most aggressive tumors due to the absence of effective diagnosis at an early stage."1.51Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells. ( Fan, QX; Guo, SS; Wang, Y, 2019)
"Management of advanced intrahepatic cholangiocarcinoma (iCCA) is challenging and overall survival is poor."1.51Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. ( Gbolahan, O; Hashemi-Sadraei, N; O'Neil, B, 2019)
"The aim of this retrospective study was to clarify the effectiveness of chemotherapy with gemcitabine combined with low-dose 5-fluorouracil and cisplatin (GFP) for advanced biliary carcinoma after hepatectomy."1.46Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma. ( Arakawa, Y; Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Yamada, S, 2017)
"(Ham-1) cells both in vitro and in vivo."1.46Synergistic Effect of Forbesione From Garcinia hanburyi in Combination with 5-Fluorouracil on Cholangiocarcinoma ( Anantachoke, N; Boonmars, T; Boueroy, P; Hahnvajanawong, C; Kongsanthia, C; Reutrakul, V; Saensa-ard, S; Salao, K; Wattanawongdon, W; Wongwajana, S, 2017)
"There are limits to the standard treatment for cholangiocarcinoma (CCA) including drug resistance and side effects."1.43Targeted delivery of 5-fluorouracil to cholangiocarcinoma cells using folic acid as a targeting agent. ( Boonsiri, P; Daduang, J; Daduang, S; Limpaiboon, T; Ngernyuang, N; Seubwai, W, 2016)
"We investigated the sensitivity of intrahepatic cholangiocarcinoma (IHCCA) subtypes to chemotherapeutics and molecular targeted agents."1.42Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures. ( Alvaro, D; Bragazzi, MC; Cardinale, V; Carpino, G; Costantini, D; De Rose, AM; Di Matteo, S; Fraveto, A; Gaudio, E; Giuliante, F; Grazi, GL; Lustri, AM; Napoletano, C; Nevi, L; Renzi, A; Semeraro, R, 2015)
" In this study, we aimed to investigate the therapeutic effect of TRAIL in CCA cell lines (M213, M214 and KKU100) compared with the immortal biliary cell line, MMNK1, either alone or in combination with a subtoxic dose of 5-fluorouracil (5-FU)."1.42TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells. ( Limpaiboon, T; Sriraksa, R, 2015)
"Combination therapy with 5-FU and interferon-α was safe and may improve the prognosis of advanced biliary carcinomas."1.42Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma. ( Kanda, M; Kawai, T; Obi, S; Sato, S; Sato, T; Sugimoto, T; Yashima, Y, 2015)
"Chemoimmunotherapy has been used to treat intrahepatic cholangiocarcinoma (ICC)."1.40Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy. ( Gong, J; Homma, S; Ito, M; Kajihara, M; Kan, S; Koido, S; Namiki, Y; Odahara, S; Ohkusa, T; Okamoto, M; Sugiyama, H; Tajiri, H; Takakura, K; Tsukinaga, S; Yoshida, K; Yoshizaki, S; Yusa, S, 2014)
"Cholangiocarcinoma is categorized into intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC)."1.40Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma. ( Kasai, K; Kasai, Y; Kooka, Y; Miyamoto, Y; Oikawa, K; Oikawa, T; Sawara, K; Suzuki, A; Suzuki, Y; Takikawa, Y; Ushio, A, 2014)
"Patients were eligible if they had intrahepatic cholangiocarcinoma with liver or extrahepatic metastasis and with no prior chemotherapy."1.39Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma. ( Chauffert, B; Ghiringhelli, F; Wiazzane, N, 2013)
"We report a case of acute inflammatory demyelinating polyradiculoneuropathy (AIDP) that developed in a patient with cholangiocarcinoma after receiving oxaliplatin-based chemotherapy."1.38Acute inflammatory demyelinating polyradiculoneuropathy in a patient receiving oxaliplatin-based chemotherapy. ( Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Kim, MK; Nam, TS; Shim, HJ; Yoon, JY, 2012)
"Intrahepatic and extrahepatic cholangiocarcinoma were observed in 57 and 21 patients, respectively."1.38Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years. ( Audrain, O; Boucher, E; Boudjema, K; Le Roux, G; Manfredi, S; Mesbah, H; Pracht, M; Raoul, JL; Sulpice, L, 2012)
"Capecitabine was administered orally at a dose of 1,000 mg/m(2) twice a day for 14 days, followed by a 1-week rest period."1.38Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study. ( Han, SS; Hong, EK; Kim, CM; Kim, HB; Kim, TH; Koh, YH; Lee, WJ; Park, JW; Park, SJ; Woo, SM, 2012)
" The treatment did not cause any serious adverse events, except hypercalcemia grade I, once in 72 administrations."1.38Evaluation of efficacy, safety and tolerability of high dose-intermittent calcitriol supplementation to advanced intrahepatic cholangiocarcinoma patients--a pilot study. ( Bhudhisawasdi, V; Chamadol, N; Chur-in, S; Janeklang, S; Khuntikeo, N; Kukongviriyapan, V; Pairojkul, C; Prawan, A; Pugkhem, A; Sookprasert, A; Vaeteewoottacharn, K; Wongkham, S, 2012)
" We determined the anticancer effects of VPA combined with 5-FU in these cell lines."1.37Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. ( Hanaoka, J; Ikemoto, T; Imura, S; Ishibashi, H; Iwahashi, S; Mori, H; Morine, Y; Ochir, TL; Shimada, M; Utsunomiya, T, 2011)
"Cholangiocarcinoma has historically represented a major contraindication to liver transplantation at many centers because of its high recurrence rate and low disease-free survival rate, even after radical surgery."1.37Neoadjuvant therapy protocol and liver transplantation in combination with pancreatoduodenectomy for the treatment of hilar cholangiocarcinoma occurring in a case of primary sclerosing cholangitis: case report with a more than 8-year disease-free survival ( Bassi, D; Boccagni, P; Boetto, R; Cillo, U; D'Amico, F; D'Amico, FE; Gringeri, E; Lodo, E; Polacco, M; Vitale, A; Zanus, G, 2011)
"Patients with cholangiocarcinoma or gallbladder cancer have poor overall prognosis and their management is often complex."1.36Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma. ( Adham, M; Bancel, B; Baulieux, J; Cassier, PA; Lombard-Bohas, C; Ponchon, T; Scoazec, JY; Souquet, JC; Thevenet, C; Walter, T, 2010)
"Cholangiocarcinomas are devastating cancers that are resistant to chemotherapies."1.36Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents. ( DeMorrow, S; Frampton, GA; Lazcano, EA; Li, H; Mohamad, A, 2010)
"Cholangiocarcinoma is a serious public health in Thailand with increasing incidence and mortality rates."1.36Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. ( Chaijaroenkul, W; Itharat, A; Mahavorasirikul, W; Na-Bangchang, K; Viyanant, V, 2010)
"5 Gy, representing a dose deposited in the generous, off-target area in clinical practice, resulted in a similar pharmacokinetic profile, with a 21."1.36Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics. ( Chen, YJ; Hsieh, CH; Hsieh, YJ; Huang, YC; Liu, CY; Shueng, PW; Tai, HC; Tsai, TH; Wang, LY; Wu, LJ, 2010)
"Extrahepatic cholangiocarcinoma is a rare malignancy."1.35Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. ( Bendell, JC; Clary, BM; Clough, RW; Czito, BG; Ghafoori, AP; Hurwitz, HI; Morse, MA; Nelson, JW; Pappas, TN; Tyler, DS; Willett, CG, 2009)
" Cholangiocellular carcinoma cells (TFK-1 cells) were treated either with 8 Gy (RTB group) or 16 Gy (RTA group) (188)Re or with (188)Re irradiation (8 Gy) combined with either gemcitabine (8 Gy/Gem) or 5-fluorouracil (8 Gy/5-FU) at a dosage of 20 microg/ml medium for 4 days and subsequently compared with an untreated control group."1.35Impact of rhenium-188, gemcitabine, and 5-fluorouracil on cholangiocellular carcinoma cells: an in vitro study. ( Bantleon, R; Farkas, E; Kehlbach, R; Werner, M; Wiesinger, B; Wiskirchen, J, 2009)
"A 66-year-old man was diagnosed with hepatocellular carcinoma with Vp3 by abdominal enhanced CT."1.35[A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus]. ( Doki, Y; Eguchi, H; Hatano, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Wakasa, K, 2009)
"Cholangiocarcinoma is a malignant neoplasm arising from the biliary epithelium."1.34Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver. ( Hsieh, CB; Huang, TW; Wang, CH, 2007)
"The high and medium dosage groups were significantly different from the control group (P<0."1.34Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice. ( Ai, X; Chen, B; Li, H; Li, X; Tang, T; Xue, KY; Zheng, JW; Zou, SQ, 2007)
"The major clinical problem was the deep venous thrombosis related to the central venous catheter, which occurred in 5 patients (17%)."1.33Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. ( Cantore, M; Caudana, R; Fiorentini, G; Lombardi, M; Mambrini, A; Nicoli, N; Pennucci, C; Rabbi, C; Sanguinetti, F; Zamagni, D, 2005)
"She was first diagnosed as intrahepatic cholangiocarcinoma with hepatic, paraaortic lymphnodal and bone metastasis."1.33[A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy]. ( Hibi, T; Higuchi, H; Hisamatsu, T; Iizuka, H; Iwasaki, E; Izumiya, M; Masaoka, T; Nagata, H; Nishizawa, T; Suzuki, H; Takaishi, H; Yamagishi, Y, 2006)
"Results of liver transplantation in the treatment of cholangiocarcinoma have been poor as a result of the high incidence of locoregional dissemination and tumor recurrence."1.31Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. ( Chinnakotla, S; DeRoover, A; Fox, I; Langnas, A; McCashland, T; Shaw, B; Sorrell, M; Sudan, D; Tempero, M, 2002)
"The first site of disease progression was local in 72% of cases."1.31Limitations of conventional doses of chemoradiation for unresectable biliary cancer. ( Brown, T; Charnsangavej, C; Crane, CH; Curley, S; Delclos, M; Janjan, NA; Macdonald, KO; Vauthey, JN; Wong, A; Yehuda, P, 2002)
"Cholangiocarcinoma is a virtually incurable tumor, resistant to current surgical, chemotherapy, and radiotherapy interventions."1.30Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. ( Buchsbaum, DJ; Curiel, DT; Kancharla, SR; Mayo, MS; Pederson, LC; Stackhouse, MA; Vickers, SM, 1997)
"Cholangiocarcinoma is the second most common primary tumor of the liver after hepatocellular carcinoma and accounts for 5 to 25% of primary hepatic malignancies."1.30Long-term survival of a young woman with peripheral cholangiocarcinoma: a case report. ( Chabot, J; Ishak, KG; Lefkowitch, J; Marvin, MR, 1999)
"A patient with advanced intrahepatic cholangiocarcinoma had a tumor embolus in the right main branch of the portal vein and lymph node metastases."1.30[A case report: successful resection of advanced intrahepatic cholangiocarcinoma responding to preoperative hepatic artery infusion of 5-FU]. ( Fujita, J; Hasuike, Y; Hattori, T; Hosoki, T; Kikkawa, N; Mishima, H; Mitomo, M; Motoori, M; Nishishou, I; Sai, H; Sawamura, T, 1999)

Research

Studies (163)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's8 (4.91)18.2507
2000's44 (26.99)29.6817
2010's88 (53.99)24.3611
2020's23 (14.11)2.80

Authors

AuthorsStudies
Qiu, C1
Hu, Y1
Wu, K1
Yang, K2
Wang, N1
Ma, Y1
Zhu, H1
Zhang, Y1
Zhou, Y2
Chen, C1
Li, S1
Fu, L1
Zhang, X2
Liu, Z1
Sribuhom, T1
Boueroy, P2
Hahnvajanawong, C5
Phatchana, R1
Yenjai, C1
Klinhom-On, N1
Seubwai, W5
Sawanyawisuth, K2
Obchoei, S1
Mahalapbutr, P1
Wongkham, S5
Martviset, P1
Panrit, L1
Chantree, P1
Muhamad, P1
Na-Bangchang, K5
Ishii, M1
Itano, O1
Morinaga, J1
Shirakawa, H1
Itano, S1
Chen, M1
Li, Y1
Ma, N1
Zang, J1
Sonsomnuek, P1
Tarasuk, M1
Plengsuriyakarn, T1
Boonprasert, K1
Huang, P1
Huang, X1
Yang, G1
Sun, Q1
Shi, G1
Chen, Y1
Cosgrove, DP1
Reese, ES1
Fulcher, NM1
Bobiak, SS1
Lamy, FX1
Allignol, A1
Boyd, M1
Mahmoudpour, SH1
Roth, GS3
Neuzillet, C3
Sarabi, M3
Edeline, J3
Malka, D3
Lièvre, A3
Chueh, CH1
Tsai, YW1
Chen, ZR1
Shiu, MN1
Wen, YW1
Chiang, NJ1
Yamagata, M1
Nakajima, T2
Aihara, T1
Nishijima, N1
Tomoo, Y1
Matsuki, G1
Fujikawa, M1
Ichise, N1
Kasai, M1
Okamoto, R1
Ikuta, S1
Nakamoto, Y1
Osaki, Y1
Yanagi, H1
Yamanaka, N2
Du, H1
Hou, S1
Zhang, L1
Liu, C2
Yu, T1
Zhang, W2
Fu, Z1
Ma, K1
Dong, B1
Zhao, C1
Che, C1
Dong, C1
Zhang, R2
Wang, H2
Wang, X2
Liang, R1
Wattanavises, S1
Silsirivanit, A1
Cha'on, U1
Waraasawapati, S2
Saentaweesuk, W1
Luang, S1
Chalermwat, C1
Wongkham, C1
Smart, AC1
Goyal, L1
Horick, N1
Petkovska, N1
Zhu, AX3
Ferrone, CR1
Tanabe, KK1
Allen, JN1
Drapek, LC1
Qadan, M1
Murphy, JE1
Eyler, CE1
Ryan, DP1
Hong, TS1
Wo, JY1
Yang, J1
Wang, J1
Zhou, H1
Wang, Y5
Huang, H1
Jin, H1
Lou, Q1
Shah, RJ1
Oguz, S1
Kucukaslan, H1
Topaloglu, S1
Ones, T1
Baltacioglu, F1
Cobanoglu, U1
Calik, A1
Permpoon, U1
Khan, F1
Vadevoo, SMP1
Gurung, S1
Gunassekaran, GR1
Kim, MJ1
Kim, SH1
Thuwajit, P1
Lee, B1
Gaddam, S1
Coté, GA1
Sardar, M1
Shroff, RT1
Jones, O1
Cheng, X1
Murthy, SRK1
Ly, L1
Zhuang, T1
Basadonna, G1
Keidar, M1
Canady, J1
Chen, L1
Chen, W1
Xu, S1
Tang, L1
Yang, Y1
Li, Q2
Jiang, Q1
Miao, L2
Zou, L1
Li, X2
Wu, X2
Cui, J1
Cui, X1
Song, X1
Ren, T1
Han, X1
Zhu, Y1
Li, H3
Wu, W1
Gong, W1
Wang, L1
Li, M1
Lau, WY2
Liu, Y2
Prompipak, J1
Senawong, T1
Sripa, B5
Ketterman, AJ1
Utaiwat, S1
Woranam, K1
Jeeunngoi, J1
Senawong, G1
Malacrida, A1
Rigolio, R1
Celio, L1
Damian, S1
Cavaletti, G1
Mazzaferro, V1
Miloso, M1
Song, S1
Yang, W1
Tian, H1
Gong, S1
Lei, C1
Lv, K1
Lu, T1
Cheng, Q1
Guo, T1
Woo, SM3
Morine, Y2
Shimada, M2
Ikemoto, T2
Arakawa, Y1
Iwahashi, S2
Saito, YU1
Yamada, S1
Imura, S2
Bruckner, HW1
Gurell, D1
Hirschfeld, A1
Boonmars, T2
Saensa-ard, S1
Wattanawongdon, W2
Kongsanthia, C1
Salao, K1
Wongwajana, S1
Anantachoke, N1
Reutrakul, V1
Kobayashi, S4
Terashima, T1
Shiba, S1
Yoshida, Y1
Yamada, I1
Iwadou, S1
Horiguchi, S1
Takahashi, H1
Suzuki, E1
Moriguchi, M1
Tsuji, K1
Otsuka, T1
Asagi, A1
Kojima, Y2
Takada, R1
Morizane, C1
Mizuno, N1
Ikeda, M1
Ueno, M1
Furuse, J1
Srijiwangsa, P1
Ponnikorn, S1
Liotta, L1
Quante, M1
Intuyod, K1
Saavedra-García, P1
Zona, S1
Lai, CF1
Jiramongkol, Y1
Vaeteewoottacharn, K3
Pairojkul, C3
Yao, S1
Yong, JS1
Trakansuebkul, S1
Luvira, V1
Pinlaor, S1
Lam, EW1
Miyata, T1
Beppu, T2
Imamura, YU1
Hayashi, H2
Imai, K1
Chikamoto, A1
Yamashita, YI1
Fukubayashi, K1
Ishiko, T2
Baba, H2
Qiu, G1
Ma, D1
Li, F1
Sun, D1
Zeng, Z1
Bisello, S1
Buwenge, M1
Palloni, A1
Autorino, R1
Cellini, F1
Macchia, G1
Deodato, F1
Cilla, S1
Brandi, G1
Tagliaferri, L1
Cammelli, S1
Valentini, V1
Morganti, AG1
Mattiucci, GC1
Gbolahan, O1
Hashemi-Sadraei, N1
O'Neil, B1
Guo, SS1
Fan, QX1
Sookprasert, A2
Pugkhem, A2
Khuntikeo, N3
Chur-in, S1
Chamadol, N1
Prawan, A3
Janeklang, S1
Kukongviriyapan, V3
Bhudhisawasdi, V3
Lange, S1
Lampe, J1
Bossow, S1
Zimmermann, M1
Neubert, W1
Bitzer, M1
Lauer, UM1
Duignan, S1
Maguire, D1
Ravichand, CS1
Geoghegan, J1
Hoti, E1
Fennelly, D1
Armstrong, J1
Rock, K1
Mohan, H1
Traynor, O1
Ge, X1
Yu, H1
Ji, G1
Wiazzane, N1
Chauffert, B1
Ghiringhelli, F2
Wirasorn, K1
Ngamprasertchai, T1
Pakkhem, A1
Ungarereevittaya, P1
Chindaprasirt, J1
Butthongkomvong, K1
Sirachainan, E1
Jhankumpha, S1
Kumdang, S1
Sukhontharot, OU1
Sinn, M1
Nicolaou, A1
Ricke, J1
Podrabsky, P1
Seehofer, D1
Gebauer, B1
Pech, M1
Neuhaus, P1
Dörken, B2
Riess, H2
Hildebrandt, B1
Welling, TH2
Feng, M1
Wan, S1
Hwang, SY1
Volk, ML1
Lawrence, TS1
Zalupski, MM2
Sonnenday, CJ1
Kim, YI1
Park, JW2
Kim, BH1
Kim, TH2
Koh, YH2
Lee, WJ2
Kim, CM2
Zeekpudsa, P1
Senggunprai, L2
Goldberg, SN1
Zhang, F1
Le, T1
Zhang, T1
Meng, Y1
Wei, B1
Soriano, SS1
Willis, P1
Kolokythas, O1
Yang, X1
Hickey, R1
Mulcahy, MF1
Lewandowski, RJ1
Gates, VL1
Vouche, M1
Habib, A1
Kircher, S1
Newman, S1
Nimeiri, H1
Benson, AB2
Salem, R1
Wu, WR1
Shi, XD1
Zhu, MS1
Xu, LB1
Zeng, H1
Kasai, K1
Kooka, Y1
Suzuki, Y1
Suzuki, A1
Oikawa, T1
Ushio, A1
Kasai, Y1
Sawara, K1
Miyamoto, Y1
Oikawa, K1
Takikawa, Y1
Hong, MJ1
Cheon, YK1
Lee, EJ1
Lee, TY1
Shim, CS1
Sio, TT1
Martenson, JA1
Haddock, MG2
Novotny, PJ1
Gores, GJ2
Alberts, SR3
Miller, RC1
Heimbach, JK1
Rosen, CB2
Koido, S1
Kan, S1
Yoshida, K1
Yoshizaki, S1
Takakura, K1
Namiki, Y1
Tsukinaga, S1
Odahara, S1
Kajihara, M1
Okamoto, M1
Ito, M1
Yusa, S1
Gong, J1
Sugiyama, H1
Ohkusa, T1
Homma, S1
Tajiri, H1
Patkowski, W1
Stankiewicz, R1
Grąt, M1
Krasnodębski, M1
Kornasiewicz, O1
Krawczyk, M1
Huang, GL2
Shen, DY2
Cai, CF1
Zhang, QY1
Ren, HY2
Chen, QX1
Samatiwat, P1
Guion-Dusserre, JF1
Lorgis, V1
Vincent, J1
Bengrine, L1
Yashima, Y1
Sato, S1
Kawai, T1
Sugimoto, T1
Sato, T2
Kanda, M1
Obi, S1
Hong, ZF1
Zhao, WX1
Yin, ZY1
Xie, CR1
Xu, YP1
Chi, XQ1
Zhang, S1
Wang, XM1
Li, J2
Wang, Q1
Lei, Z1
Wu, D1
Si, A1
Wang, K1
Wan, X1
Yan, Z1
Xia, Y1
Wu, M1
Shen, F1
Ben-Josef, E1
Guthrie, KA1
El-Khoueiry, AB2
Corless, CL1
Lowy, AM1
Thomas, CR1
Dawson, LA1
Micetich, KC1
Thomas, MB1
Siegel, AB1
Blanke, CD2
Namwat, N3
Kanchanawat, S1
Jearanaikoon, P4
Leelayuwat, C2
Techasen, A2
Nutthasirikul, N1
Limpaiboon, T4
Chau-In, S1
Massani, M1
Nistri, C1
Ruffolo, C1
Bonariol, R1
Pauletti, B1
Bonariol, L1
Caratozzolo, E1
Morana, G1
Bassi, N1
Sriraksa, R1
Park, KW1
Seo, CJ1
Yun, DY1
Kim, MK2
Kim, BS1
Han, YS1
Oh, HK1
Lee, CH1
Fraveto, A1
Cardinale, V1
Bragazzi, MC1
Giuliante, F1
De Rose, AM1
Grazi, GL1
Napoletano, C1
Semeraro, R1
Lustri, AM1
Costantini, D1
Nevi, L1
Di Matteo, S1
Renzi, A1
Carpino, G1
Gaudio, E1
Alvaro, D1
Konstantinidis, IT1
Groot Koerkamp, B1
Do, RK1
Gönen, M1
Fong, Y1
Allen, PJ1
D'Angelica, MI1
Kingham, TP1
DeMatteo, RP1
Klimstra, DS1
Kemeny, NE1
Jarnagin, WR1
Ngernyuang, N1
Daduang, S1
Boonsiri, P1
Daduang, J1
Kraiklang, R1
Umezawa, K1
Okada, S1
Wentrup, R1
Winkelmann, N1
Mitroshkin, A1
Prager, M1
Voderholzer, W1
Schachschal, G1
Jürgensen, C1
Büning, C1
Endlicher, E1
Schnoy, E1
Troppmann, M1
Rogler, G1
Messmann, H1
Klebl, F1
Gelbmann, C1
Kullmann, F1
Chen, B2
Kato, S1
Takeuchi, Y1
Wada, N1
Morimoto, Y1
Kuwaki, K1
Ohnishi, H1
Nakamura, S1
Shiraha, H1
Takaki, A1
Okada, H1
Hasuike, Y4
Higuchi, I1
Hosomi, S1
Ishikawa, A2
Akiyama, Y1
Tanigawa, T1
Okada, A1
Yu, ZY1
Ouyang, XN1
Chen, ZS1
Chen, X1
Xie, FW1
Amimanan, P1
Loilome, W1
Tassaneeyakul, W2
Nelson, JW1
Ghafoori, AP1
Willett, CG1
Tyler, DS1
Pappas, TN1
Clary, BM1
Hurwitz, HI1
Bendell, JC1
Morse, MA1
Clough, RW1
Czito, BG1
Noda, T1
Nagano, H4
Marubashi, S3
Takeda, Y2
Murakami, M2
Tomimaru, Y3
Dono, K2
Umeshita, K2
Nakayama, M1
Shima, T1
Wakasa, K2
Monden, M2
Doki, Y3
Mori, M3
Gennatas, C1
Michalaki, V1
Gennatas, S1
Lang, M1
Henson, R2
Braconi, C1
Patel, T2
Honda, K1
Hamada, H1
Kobayashi, N2
Singal, A1
Marrero, JA1
Wiesinger, B1
Farkas, E1
Kehlbach, R1
Bantleon, R1
Werner, M1
Wiskirchen, J1
Hatano, H1
Tomokuni, A1
Eguchi, H2
Tanemura, M1
Yokoo, H1
Kamiyama, T1
Nakagawa, T1
Nakanishi, K1
Tahara, M1
Fukumori, D1
Kamachi, H1
Matsushita, M1
Todo, S1
Gerhardt, T1
Rings, D1
Höblinger, A1
Heller, J1
Sauerbruch, T1
Schepke, M1
Louvet, C1
Tournigand, C1
Chang, PY1
Cheng, MF1
Lee, HS1
Hsieh, CB2
Yao, NS1
Hsieh, CH1
Hsieh, YJ1
Liu, CY1
Tai, HC1
Huang, YC1
Shueng, PW1
Wu, LJ1
Wang, LY1
Tsai, TH1
Chen, YJ1
Thanasai, J1
Tantimavanich, S1
Miwa, M1
Nagai, K1
Ishii, H1
Miyoshi, N1
Hoshino, H1
Saito, T1
Sekimoto, M1
Cassier, PA1
Thevenet, C1
Walter, T1
Baulieux, J1
Scoazec, JY1
Bancel, B1
Adham, M1
Souquet, JC1
Ponchon, T1
Lombard-Bohas, C1
Yürek, S1
Kreher, S1
Salama, A1
Frampton, GA1
Lazcano, EA1
Mohamad, A1
DeMorrow, S1
Lassen, U1
Jensen, LH2
Sorensen, M1
Rohrberg, KS1
Ujmajuridze, Z1
Jakobsen, A2
Mahavorasirikul, W2
Viyanant, V2
Chaijaroenkul, W2
Itharat, A1
Ishibashi, H1
Utsunomiya, T1
Ochir, TL1
Hanaoka, J1
Mori, H1
Iqbal, S1
Rankin, C1
Lenz, HJ1
Gold, PJ1
Ahmad, SA1
Messino, MJ1
Holcombe, RF1
Kitahara, H1
Masumoto, J1
Parker, AL1
Maruta, F1
Kubo, N1
Shimizu, A1
Akita, N1
Miwa, S1
Nakayama, J1
Miyagawa, S1
Gringeri, E1
Bassi, D1
D'Amico, FE1
Boetto, R1
Polacco, M1
Lodo, E1
D'Amico, F1
Vitale, A1
Boccagni, P1
Zanus, G1
Cillo, U1
Bonet Beltrán, M1
Roth, AD1
Mentha, G1
Allal, AS1
Thrum, S1
Lorenz, J1
Mössner, J1
Wiedmann, M1
Tani, S1
Murata, S1
Tamura, M1
Fukunaga, K1
Morita, M1
Hirata, Y1
Iida, H1
Kakuno, A1
Nishigami, T1
Lindebjerg, J1
Ploen, J1
Hansen, TF1
Yoon, JY1
Nam, TS1
Hwang, JE1
Shim, HJ1
Cho, SH1
Chung, IJ1
Bae, WK1
Pracht, M1
Le Roux, G1
Sulpice, L1
Mesbah, H1
Manfredi, S1
Audrain, O1
Boudjema, K1
Raoul, JL1
Boucher, E1
Han, SS1
Park, SJ1
Kim, HB1
Hong, EK1
Chaiyagool, J1
Croitoru, A1
Gramaticu, I1
Dinu, I1
Gheorghe, L1
Alexandrescu, S1
Buica, F1
Luca, I1
Becheanu, G1
Herlea, V1
Simionov, I1
Hrehoret, D1
Lupescu, I1
Popescu, I1
Diculescu, M1
Turaga, KK1
Tsai, S1
Wiebe, LA1
Evans, DB1
Gamblin, TC1
Knox, JJ2
Iwagami, Y1
Kira, T1
Hirao, S1
Komatsu, H1
Kanazawa, A1
Tsukamoto, T1
Shimizu, S1
Mori, Y1
Ohira, G1
Kodai, S1
Morimoto, J1
Yamazoe, S1
Yamamoto, A1
Inoue, T1
Yamashita, Y1
Nishiguchi, Y1
Ikehara, T1
Taira, K1
Horii, K1
Yamazaki, O1
Gardini, A1
Saragoni, L1
La Barba, G1
Serra, L1
Calistri, D1
Ulivi, P1
Casadei, A1
Frassineti, GL1
Garcea, D1
Taïeb, J1
Mitry, E1
Boige, V1
Artru, P1
Ezenfis, J1
Lecomte, T1
Clavero-Fabri, MC1
Vaillant, JN1
Rougier, P1
Ducreux, M1
Sudan, D1
DeRoover, A1
Chinnakotla, S1
Fox, I1
Shaw, B1
McCashland, T1
Sorrell, M1
Tempero, M1
Langnas, A1
Cantore, M2
Rabbi, C2
Guadagni, S1
Zamagni, D2
Aitini, E1
Lee, MA1
Woo, IS1
Kang, JH1
Hong, YS1
Lee, KS1
Hedley, D1
Oza, A1
Siu, LL1
Pond, GR1
Moore, MJ1
Hofheinz, RD1
Willer, A1
Weisser, A1
Gnad, U1
Saussele, S1
Kreil, S1
Hartmann, JT1
Hehlmann, R1
Hochhaus, A1
Patt, YZ2
Hassan, MM1
Aguayo, A1
Nooka, AK1
Lozano, RD1
Curley, SA1
Vauthey, JN2
Ellis, LM1
Schnirer, II1
Wolff, RA1
Charnsangavej, C3
Brown, TD1
Enjoji, M1
Yamaguchi, K1
Nakamuta, M1
Nakashima, M1
Kotoh, K1
Tanaka, M1
Nawata, H1
Watanabe, T1
Kelley, ST1
Bloomston, M1
Serafini, F1
Carey, LC1
Karl, RC1
Zervos, E1
Goldin, S1
Rosemurgy, P1
Rosemurgy, AS1
Wada, H1
Kondo, M1
Yamamoto, T1
Ota, H1
Nakamura, M1
Yoshioka, S1
Damdinsuren, B1
Yubo, Y1
Miyamoto, A1
Nakamori, S2
Sakon, M1
Al-Khatib, H1
Mahoney, MR1
Burgart, L2
Cera, PJ1
Flynn, PJ1
Finch, TR1
Levitt, R1
Windschitl, HE1
Knost, JA1
Tschetter, LK1
Mambrini, A1
Fiorentini, G1
Caudana, R1
Pennucci, C1
Sanguinetti, F1
Lombardi, M1
Nicoli, N1
Thongprasert, S1
Akita, H1
Yamada, T1
Sasaki, Y2
Ohigashi, H2
Ishikawa, O2
Imaoka, S2
Hayashi, N1
Fukuchi, N1
Kida, H1
Tujie, M1
Yoshida, T2
Ebisui, C1
Sakita, I1
Koshino, T1
Izumiyama, K1
Koro, T1
Fujimoto, T1
Tai, CJ1
Chiou, HY1
Wu, CH1
Pan, S1
Liu, JD1
Naus, PJ1
Bleeker, G1
Wehbe, H1
Meng, F1
Nishizawa, T1
Higuchi, H1
Takaishi, H1
Iizuka, H1
Izumiya, M1
Yamagishi, Y1
Hisamatsu, T1
Suzuki, H1
Masaoka, T1
Iwasaki, E1
Nagata, H1
Hibi, T1
Mizumoto, T1
Masuda, T1
Okabe, K1
Baba, Y1
Okabe, H1
Takamori, H1
Kanemitsu, K1
Hiroto, M1
Huang, TW1
Wang, CH1
Slupski, MW1
Szczylik, C1
Jasinski, MK1
Tang, T1
Zheng, JW1
Xue, KY1
Ai, X1
Zou, SQ1
Iyer, RV1
Gibbs, J1
Kuvshinoff, B1
Fakih, M1
Kepner, J1
Soehnlein, N1
Lawrence, D1
Javle, MM1
Hezel, AF1
Whittington, R1
Neuberg, D1
Tester, WJ1
Haller, DG1
Jones, DV1
Hoque, A1
Lozano, R1
Markowitz, A1
Raijman, I1
Lynch, P1
Nakano, H1
Furukawa, H1
Kabuto, T1
Kameyama, M1
Hiratsuka, M1
Yasuda, T1
Iwanaga, T1
Pederson, LC1
Buchsbaum, DJ1
Vickers, SM1
Kancharla, SR1
Mayo, MS1
Curiel, DT1
Stackhouse, MA1
Takao, T1
Nishida, M1
Maeda, Y1
Takao, K1
Oka, M1
Sanz-Altamira, PM1
Ferrante, K1
Jenkins, RL1
Lewis, WD1
Huberman, MS1
Stuart, KE1
Marvin, MR1
Lefkowitch, J1
Ishak, KG1
Chabot, J1
Motoori, M1
Hattori, T1
Fujita, J1
Mishima, H1
Sawamura, T1
Nishishou, I1
Kikkawa, N1
Sai, H1
Hosoki, T1
Mitomo, M1
De Vreede, I1
Steers, JL1
Burch, PA1
Gunderson, LL1
Garner, PD1
Hall, LD1
Johnstone, PA1
Mehta, VK1
Fisher, GA1
Ford, JM1
Poen, JC1
Vierra, MA1
Oberhelman, HA1
Bastidas, AJ1
Chen, JS1
Lin, YC1
Jan, YY1
Liau, CT1
Tanaka, N1
Yamakado, K1
Nakatsuka, A1
Fujii, A1
Matsumura, K1
Takeda, K1
Matsumoto, T1
Sasaki, A1
Morii, Y1
Aramaki, M1
Kitano, S1
Bouras, N1
Caudry, M1
Saric, J1
Bonnel, C1
Rullier, E1
Trouette, R1
Demeaux, H1
Maire, JP1
Stemmler, J1
Heinemann, V1
Schalhorn, A1
Crane, CH1
Macdonald, KO1
Yehuda, P1
Brown, T1
Curley, S1
Wong, A1
Delclos, M1
Janjan, NA1

Clinical Trials (18)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Endobiliary Radiofrequency Ablation With S-1 in Patients With Unresectable Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control[NCT02592538]66 participants (Actual)Interventional2015-12-31Completed
Modified FOLFIRINOX Versus Gemcitabine Plus Oxaliplatin as First-line Chemotherapy for Patients With Locally Advanced or Metastatic Cholangiocarcinoma[NCT04305288]100 participants (Anticipated)Observational2016-01-01Recruiting
"TACE Combined With Target Immune Therapy for First-line Treatment Compared With Intravenous Chemotherapy in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: A Prospective, Multicenter, Open, Real-World Clinical Study"[NCT05247996]98 participants (Anticipated)Interventional2022-03-01Not yet recruiting
A Clinical Trial Phase II of Calcitriol in Combination With 5-fluorouracil, Mitomycin C and Leucovorin in an Open Label-non-randomized Study to Evaluate the Tumor Response in Patients With Advanced Intrahepatic Cholangiocarcinoma[NCT01039181]Phase 228 participants (Anticipated)Interventional2010-01-31Not yet recruiting
A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681]Phase 26 participants (Actual)Interventional2014-09-30Terminated (stopped due to lack of funding)
UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors[NCT04339036]Phase 250 participants (Anticipated)Interventional2021-10-07Recruiting
Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562]Phase 228 participants (Anticipated)Interventional2021-10-28Active, not recruiting
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)[NCT00789958]Phase 2105 participants (Actual)Interventional2008-12-31Completed
A Randomized Controlled, Open Labeled, Two Arm, Study of Addition of Everolimus to Standard of Care in Carcinoma Gallbladder[NCT05833815]Phase 2/Phase 356 participants (Anticipated)Interventional2022-11-01Recruiting
A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma[NCT00033540]Phase 257 participants (Actual)Interventional2003-09-30Completed
Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma[NCT00779454]Phase 272 participants (Actual)Interventional2008-09-30Completed
Prospective Registry Study of Neoadjuvant Therapy in Conjunction With Liver Transplantation for Cholangiocarcinoma[NCT00301379]59 participants (Actual)Observational2005-08-12Terminated (stopped due to Low accrual)
A Single-Arm Nonrandomized Phase II Study of Liver Transplantation in Locally Advanced Unresectable Non-Metastatic Intrahepatic Cholangiocarcinoma Treated With Neoadjuvant Systemic Therapy[NCT06140134]30 participants (Anticipated)Observational [Patient Registry]2023-12-31Not yet recruiting
Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis[NCT03079427]Phase 2101 participants (Actual)Interventional2017-05-15Completed
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320]Phase 2200 participants (Actual)Interventional2015-10-05Active, not recruiting
Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma[NCT00009893]Phase 242 participants (Actual)Interventional2001-05-31Completed
Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703]Phase 238 participants (Actual)Interventional2005-08-31Completed
Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma[NCT02548195]Phase 3286 participants (Anticipated)Interventional2015-07-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Intrahepatic Disease Progression After Treatment With Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.

InterventionParticipants (Count of Participants)
Treatment6

Number of Participants With Intrahepatic Recurrence After Partial Hepatectomy With Antecedent Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.

InterventionParticipants (Count of Participants)
Treatment1

Number of Participants With Post-operative Complications After Partial Hepatectomy After Antecedent Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy

InterventionParticipants (Count of Participants)
Treatment1

2-year Disease-free Survival in All Patients

Disease-free survival is calculated from date of registration to date of first documentation of relapse or death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration

Interventionpercentage of participants (Number)
Adjuvant Chemotherapy + Chemoradiotherapy52

2-year Overall Local Relapse Rate

Local relapse is any evidence of new disease within the primary tumor bed or the regional (retroperitoneal, celiac, and portal vein nodes) lymphatics (these areas are to be encompassed within the radiation fields). (NCT00789958)
Timeframe: Up to 2 years from registration

Interventionpercentage of participants (Number)
Adjuvant Chemotherapy + Chemoradiotherapy11

2-year Overall Survival for All Patients

Time to death is calculated from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration

Interventionpercentage of participants (Number)
Adjuvant Chemotherapy + Chemoradiotherapy65

2-year Stratum-specific Disease-free Survival

Disease-free survival is calculated from date of registration to date of first documentation of relapse or death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration

Interventionpercentage of participants (Number)
Patients With Negative Margins of Resection (R0)54
Patients w/Microscopically Positive Margin of Resection (R1)48

2-year Stratum-specific Local Relapse Rate

Local relapse is any evidence of new disease within the primary tumor bed or the regional (retroperitoneal, celiac, and portal vein nodes) lymphatics (these areas are to be encompassed within the radiation fields). (NCT00789958)
Timeframe: Up to 2 years from registration

Interventionpercentage of participants (Number)
Patients With Negative Margins of Resection (R0)9
Patients w/Microscopically Positive Margin of Resection (R1)16

Stratum-specific (R0 and R1) 2-year Overall Survival

Time to death is calculated from date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT00789958)
Timeframe: Up to 2 years from registration

Interventionpercentage of participants (Number)
Patients With Negative Margins of Resection (R0)67
Patients w/Microscopically Positive Margin of Resection (R1)60

Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug

Only adverse events that are possibly, probably or definitely related to study drug are reported. (NCT00789958)
Timeframe: Up to 5 years

InterventionParticipants (Number)
AnorexiaCardiac troponin I (cTnI)ConstipationDehydrationDiarrheaFatigue (asthenia, lethargy, malaise)Febrile neutropeniaHemoglobinHemorrhage, GI - DuodenumHemorrhage, GI - Lower GI NOSHypotensionLung Infection w/normal ANC or Gr 1-2 neutrophilsSkin Infection w/normal ANC or Gr 1-2 neutrophilsInfection-Other (Specify)Leukocytes (total WBC)LymphopeniaMucositis/stomatitis (clinical exam) - Oral cavityNeuropathy: sensoryNeutrophils/granulocytes (ANC/AGC)Phosphate, serum-low (hypophosphatemia)PlateletsPotassium, serum-low (hypokalemia)Rash/desquamationRash: hand-foot skin reactionSodium, serum-low (hyponatremia)Syncope (fainting)Thrombosis/embolism (vascular access-related)Thrombosis/thrombus/embolismUlcer, GI - DuodenumVentricular arrhythmia - Ventricular tachycardia
Adjuvant Chemotherapy + Chemoradiotherapy11116411111111562135122110111111

Overall Survival

Measured from time of registration to death, or last contact date (NCT00033540)
Timeframe: All patients will be followed until death or three years after registration, whichever is first.

Interventionmonths (Median)
Capecitabine + Gemcitabine7

Accrual of Patients With This Disease Site

Only eligible patients who received treatment were evaluable for response and survival outcomes. (NCT00033540)
Timeframe: 1-20 months

Interventionparticipants (Number)
EligibleEligible and Analyzable
Capecitabine + Gemcitabine5452

Median Survival Time for Participants With Relevant Biologic Markers

To evaluate in a preliminary fashion relevant prognostic markers in gallbladder and cholangiocarcinoma which may have prognostic implications as predictors of survival. Overall survival measured from time of registration to death, or last contact date. (NCT00033540)
Timeframe: All patients will be followed until death or three years after registration, whichever is first.

Interventionmonths (Median)
TS 3' +/+ (N=14)TS 3' +/- (N=6)TS 3' -/- (N=2)TS 5' Low functional significance (N=16)TS 5' Intermediate functional significance (N=16)MTHFR C677T - C/C (N=11)MTHFR C677T - C/T (N=11)MTHFR A1298C - A/A (N=11)MTHFR A1298C - A/C (N=8)MTHFR A1298C - C/C (N=3)RRMI G/A - G/G (N=9)RRMI G/A - G/A (N=10)RRMI G/A - A/A (N=3)CDA A79C - A/A (N=8)CDA A79C - A/C (N=12)CDA A79C - C/C (N=1)
Capecitabine + Gemcitabine779976774979547NA

Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug

Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0. Any CTCAE 3.0 event of Grade 3 (severe), Grade 4 (life threatening) or Grade 5 (fatal) which were deemed to be related to protocol treatment are included. For each patient, worst grade of each event type is reported. (NCT00033540)
Timeframe: Patients were assessed for adverse events 3 weeks after starting treatment. Assessments for adverse events continued every 3 weeks for the duration of protocol treatment.

InterventionParticipants (Number)
ALT, SGPT (serum glutamic pyruvic transaminase)AST,SGOT (serum glutamic oxaloacetic transaminase)Albumin, serum-low (hypoalbuminemia)Alkaline phosphataseAnorexiaAscites (non-malignant)Bilirubin (hyperbilirubinemia)ConstipationCreatinineDehydrationDiarrheaDysphagia (difficulty swallowing)Fatigue (asthenia, lethargy, malaise)HemoglobinHemolysisHemorrhage, GI - EsophagusInfection w/Grade 3-4 neutrophils - Upper airwayInfection with normal ANC or Grade 1-2 neutrophilsLeukocytes (total WBC)Mucositis/stomatitis (clinical exam) - Oral cavityMucositis/stomatitis (function/symp)-Oral cavityMuscle weakness (not due to neuropathy)NauseaNeutrophils/granulocytes (ANC/AGC)Pain - Abdomen NOSPain - JointPain - MusclePain - Tumor painPlateletsPotassium, serum-low (hypokalemia)Rash: hand-foot skin reactionSupraventricular nodal arrhythmiaThrombosis/thrombus/embolismVomiting
Gemcitabine and Capecitabine151521411311861111911131621111224112

Response

Complete Response (CR) is complete disappearance of all measurable and non-measurable disease. No new lesions, no disease related symptoms. Normalization of markers and other abnormal lab values. Partial Response (PR) is greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Confirmation of CR or PR means a repeat scan at least 4 weeks apart documented before progression or symptomatic deterioration. Progression is 20% increase in sum of longest diameters of target measurable lesions over smallest sum observed and/or unequivocal progression of non-measurable disease and/or appearance of new lesion/site or death due to disease without prior documentation of progression and without symptomatic deterioration. Symptomatic deterioration is global deterioration of health status requiring discontinuation of treatment without objective evidence of progression. (NCT00033540)
Timeframe: Patients assessed at least every six weeks while on protocol treatment

Interventionparticipants (Number)
Confirmed Partial ResponseUnconfirmed Partial ResponseStable DiseaseProgressionSymptomatic DeteriorationEarly DeathInadequate Assessment
Capecitabine + Gemcitabine761215318

Reviews

10 reviews available for fluorouracil and Cholangiocellular Carcinoma

ArticleYear
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 179

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Precision M

2023
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 179

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Precision M

2023
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 179

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Precision M

2023
Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 179

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Precision M

2023
Biliary cancer: gateway to comprehensive molecular profiling.
    Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplat

2021
The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis.
    Clinics and research in hepatology and gastroenterology, 2022, Volume: 46, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bilia

2022
[Chemotherapy for Biliary Tract Cancer].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2017, Mar-25, Volume: 69, Issue:3

    Topics: Antineoplastic Agents; Bevacizumab; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycyt

2017
Intrahepatic chemotherapy for unresectable cholangiocarcinoma: review of literature and personal experience.
    Updates in surgery, 2015, Volume: 67, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma

2015
A case of unresectable combined hepatocellular cholangiocarcinoma showing favorable response to LFP therapy.
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2016, Volume: 113, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol

2016
The role of capecitabine in the management of tumors of the digestive system.
    Reviews on recent clinical trials, 2009, Volume: 4, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms

2009
Role of liver transplantation in the treatment of cholangiocarcinoma.
    Expert review of anticancer therapy, 2009, Volume: 9, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms

2009
The role of chemotherapy in cholangiocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16 Suppl 2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma;

2005
Systemic therapy for biliary tract cancers.
    The oncologist, 2008, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycy

2008

Trials

23 trials available for fluorouracil and Cholangiocellular Carcinoma

ArticleYear
Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma.
    Annals of surgical oncology, 2020, Volume: 27, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Cholangiocarcinoma; Combined Modality Therapy;

2020
Endoscopic radiofrequency ablation plus a novel oral 5-fluorouracil compound versus radiofrequency ablation alone for unresectable extrahepatic cholangiocarcinoma.
    Gastrointestinal endoscopy, 2020, Volume: 92, Issue:6

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrah

2020
[Adjuvant chemotherapy with Capecitabine as new standard for resected cholangiocarcinomas - a look at the BILCAP trial].
    Zeitschrift fur Gastroenterologie, 2018, Volume: 56, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cholangi

2018
Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161).
    BMC gastroenterology, 2013, Aug-09, Volume: 13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah

2013
Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization.
    International journal of radiation oncology, biology, physics, 2014, Apr-01, Volume: 88, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine;

2014
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Aug-20, Volume: 33, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2015
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Aug-20, Volume: 33, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2015
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Aug-20, Volume: 33, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2015
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Aug-20, Volume: 33, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2015
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah

2008
[Effects of pharmacokinetic modulation chemotherapy (PMC) using oral UFT and venous 5-FU infusion as adjuvant chemotherapy for intrahepatic cholangiocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr

2009
A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
    Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah

2011
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2011
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2012
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2012
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2012
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2012
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2002
Intra-arterial hepatic chemotherapy combined with continuous infusion of 5-fluorouracil in patients with metastatic cholangiocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Disease Progres

2002
Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma.
    Journal of cancer research and clinical oncology, 2004, Volume: 130, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Drug Adm

2004
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi

2004
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.
    British journal of cancer, 2004, May-17, Volume: 90, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Dox

2004
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Cancer, 2005, Jan-01, Volume: 103, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2005
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Cancer, 2005, Jan-01, Volume: 103, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2005
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Cancer, 2005, Jan-01, Volume: 103, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2005
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Cancer, 2005, Jan-01, Volume: 103, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2005
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
    Annals of surgical oncology, 2007, Volume: 14, Issue:11

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct N

2007
Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:1

    Topics: Adult; Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Th

1995
Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neop

1996
A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma.
    Cancer, 1998, Jun-15, Volume: 82, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ca

1998
Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of Vater: preliminary report.
    Archives of surgery (Chicago, Ill. : 1960), 2001, Volume: 136, Issue:1

    Topics: Actuarial Analysis; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chola

2001
Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.
    Anti-cancer drugs, 2001, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bilia

2001

Other Studies

130 other studies available for fluorouracil and Cholangiocellular Carcinoma

ArticleYear
Synthesis and biological evaluation of allylated mono-carbonyl analogues of curcumin (MACs) as anti-cancer agents for cholangiocarcinoma.
    Bioorganic & medicinal chemistry letters, 2016, 12-15, Volume: 26, Issue:24

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcino

2016
Benzoyltyramine Alkaloids Atalantums A-G from the Peels of Atalantia monophylla and Their Cytotoxicity against Cholangiocarcinoma Cell Lines.
    Journal of natural products, 2017, 02-24, Volume: 80, Issue:2

    Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholang

2017
FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase.
    Life sciences, 2021, Dec-01, Volume: 286

    Topics: Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cell

2021
Suppression of Cholangiocarcinoma Cell Growth and Proliferation by Atractylodes lancea (Thunb) DC. through ERK-Signaling Cascade.
    Asian Pacific journal of cancer prevention : APJCP, 2021, Nov-01, Volume: 22, Issue:11

    Topics: Antineoplastic Agents; Atractylodes; Bile Duct Neoplasms; Cell Growth Processes; Cell Line, Tumor; C

2021
Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
    PloS one, 2022, Volume: 17, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chola

2022
Mesenchymal stem cell‑derived exosomes loaded with 5‑Fu against cholangiocarcinoma
    Molecular medicine reports, 2022, Volume: 25, Issue:6

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Exosomes; Fluorouracil; Humans; M

2022
Apoptotic and Anti-metastatic Effects of Atractylodes lancea (Thunb.) DC. in a Hamster Model of Cholangiocarcinoma.
    Asian Pacific journal of cancer prevention : APJCP, 2022, Sep-01, Volume: 23, Issue:9

    Topics: Animals; Atractylodes; bcl-2-Associated X Protein; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Ca

2022
The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
    Canadian journal of gastroenterology & hepatology, 2022, Volume: 2022

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carci

2022
Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment.
    Cancer medicine, 2023, Volume: 12, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic

2023
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy.
    PharmacoEconomics, 2023, Volume: 41, Issue:3

    Topics: Biomarkers; Cholangiocarcinoma; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Fluorouracil; Hu

2023
[Two Cases of Elderly Patients with Giant Intrahepatic Cholangiocarcinoma Treated with Multidisciplinary Therapy including Ablation Therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:13

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile D

2022
LncRNA FALEC increases the proliferation, migration and drug resistance of cholangiocarcinoma through competitive regulation of miR-20a-5p/SHOC2 axis.
    Aging, 2023, 05-09, Volume: 15, Issue:9

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Movement; Cell Proliferation;

2023
The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells.
    BMC complementary and alternative medicine, 2019, Aug-07, Volume: 19, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chol

2019
Increase of MAL-II Binding Alpha2,3-Sialylated Glycan Is Associated with 5-FU Resistance and Short Survival of Cholangiocarcinoma Patients.
    Medicina (Kaunas, Lithuania), 2019, Nov-28, Volume: 55, Issue:12

    Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangi

2019
Is it Possible to Increase Survival of Patients with Intrahepatic Cholangiocarcinoma? A Case Report.
    Journal of gastrointestinal cancer, 2021, Volume: 52, Issue:1

    Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma

2021
Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor.
    Molecular pharmaceutics, 2020, 11-02, Volume: 17, Issue:11

    Topics: Animals; Apoptosis; Bile Duct Neoplasms; Carcinogenesis; Cell Line, Tumor; Cholangiocarcinoma; Drug

2020
The importance of the "endoscopic oncologist" in the treatment of nonoperable cholangiocarcinoma.
    Gastrointestinal endoscopy, 2020, Volume: 92, Issue:6

    Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Oncologists

2020
The synergistic effect of Canady Helios cold atmospheric plasma and a FOLFIRINOX regimen for the treatment of cholangiocarcinoma in vitro.
    Scientific reports, 2021, 04-26, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cholangiocarcinoma; Dose-Response

2021
The ATO/miRNA-885-5p/MTPN axis induces reversal of drug-resistance in cholangiocarcinoma.
    Cellular oncology (Dordrecht), 2021, Volume: 44, Issue:4

    Topics: Antineoplastic Agents; Arsenic Trioxide; Bile Duct Neoplasms; Cell Line; Cell Line, Tumor; Cell Surv

2021
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study.
    BMC cancer, 2021, Jul-16, Volume: 21, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Deoxycytidine; Fema

2021
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study.
    BMC cancer, 2021, Jul-16, Volume: 21, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Deoxycytidine; Fema

2021
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study.
    BMC cancer, 2021, Jul-16, Volume: 21, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Deoxycytidine; Fema

2021
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study.
    BMC cancer, 2021, Jul-16, Volume: 21, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Deoxycytidine; Fema

2021
Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo.
    Scientific reports, 2021, 07-21, Volume: 11, Issue:1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinom

2021
In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells.
    International journal of molecular sciences, 2021, Jul-30, Volume: 22, Issue:15

    Topics: Antineoplastic Agents; Autophagy; Bile Duct Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement;

2021
Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma.
    Anticancer research, 2017, Volume: 37, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; C

2017
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
    Anticancer research, 2018, Volume: 38, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols

2018
Synergistic Effect of Forbesione From Garcinia hanburyi in Combination with 5-Fluorouracil on Cholangiocarcinoma
    Asian Pacific journal of cancer prevention : APJCP, 2017, Dec-29, Volume: 18, Issue:12

    Topics: Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Cricetinae; Drug

2017
Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
    Cancer science, 2018, Volume: 109, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2018
Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
    BMC pharmacology & toxicology, 2018, 06-19, Volume: 19, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cell Movement; Cholangiocar

2018
FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1-TYMS axis uncoupling in 5-FU resistance.
    Cell death & disease, 2018, 12-11, Volume: 9, Issue:12

    Topics: Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Drug Resistance

2018
A 12-year Recurrence-free Survival After Multidisciplinary Treatment for a Patient With Combined Hepatocellular-Cholangiocarcinoma.
    Anticancer research, 2019, Volume: 39, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol

2019
lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma.
    International journal of oncology, 2019, Volume: 55, Issue:1

    Topics: Bile Duct Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cholangiocarcinoma; Drug Resistance, Neopl

2019
Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study.
    Anticancer research, 2019, Volume: 39, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Brachytherapy;

2019
Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2019, 06-01, Volume: 17, Issue:6

    Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bile Duc

2019
Raddeanin A promotes apoptosis and ameliorates 5-fluorouracil resistance in cholangiocarcinoma cells.
    World journal of gastroenterology, 2019, Jul-14, Volume: 25, Issue:26

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cell Movement;

2019
Evaluation of efficacy, safety and tolerability of high dose-intermittent calcitriol supplementation to advanced intrahepatic cholangiocarcinoma patients--a pilot study.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13 Suppl

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepat

2012
A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma.
    Human gene therapy, 2013, Volume: 24, Issue:5

    Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Fluorouracil; Genetic Therapy; H

2013
Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2014, Volume: 16, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Brachyt

2014
NK4 regulates 5-fluorouracil sensitivity in cholangiocarcinoma cells by modulating the intrinsic apoptosis pathway.
    Oncology reports, 2013, Volume: 30, Issue:1

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Caspase 3

2013
Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2013
Adjuvant chemotherapy in resectable cholangiocarcinoma patients.
    Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2013
Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2013
Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2014, Volume: 20, Issue:1

    Topics: Aged; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cholangiocarcinoma; Cholangitis, Scler

2014
Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for advanced-stage unresectable intrahepatic cholangiocarcinoma.
    Radiation oncology (London, England), 2013, Dec-21, Volume: 8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah

2013
Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents.
    Journal of experimental & clinical cancer research : CR, 2014, Jan-24, Volume: 33

    Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Bile Duct Neoplasms; Cell Line, Tumor; Cell Pr

2014
Science to practice: Can we turn the undesired heating effects of MR imaging into effective cancer therapies?
    Radiology, 2014, Volume: 270, Issue:2

    Topics: Animals; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Humans;

2014
Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging--preclinical study.
    Radiology, 2014, Volume: 270, Issue:2

    Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Chromatography, High Pressure Li

2014
Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
    Oncology reports, 2014, Volume: 31, Issue:6

    Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Movement; Cell Proliferation; Cholangiocar

2014
Efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic pegylated interferon α-2b for advanced intrahepatic cholangiocarcinoma.
    Annals of surgical oncology, 2014, Volume: 21, Issue:11

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antivi

2014
Long-term outcome of photodynamic therapy with systemic chemotherapy compared to photodynamic therapy alone in patients with advanced hilar cholangiocarcinoma.
    Gut and liver, 2014, Volume: 8, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah

2014
Outcome of Transplant-fallout Patients With Unresectable Cholangiocarcinoma.
    American journal of clinical oncology, 2016, Volume: 39, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Brachytherapy; Capecitabine; Chem

2016
Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.
    Anticancer research, 2014, Volume: 34, Issue:11

    Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplas

2014
Poor outcomes after liver transplantation in patients with incidental cholangiocarcinoma irrespective of tumor localization.
    Transplantation proceedings, 2014, Volume: 46, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic

2014
β-escin reverses multidrug resistance through inhibition of the GSK3β/β-catenin pathway in cholangiocarcinoma.
    World journal of gastroenterology, 2015, Jan-28, Volume: 21, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; beta

2015
Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells.
    Naunyn-Schmiedeberg's archives of pharmacology, 2015, Volume: 388, Issue:6

    Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Line, Tumor; Cell Survival; Cholangiocarc

2015
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma.
    World journal of gastroenterology, 2015, Feb-21, Volume: 21, Issue:7

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2015
Intraarterial 5-fluorouracil and interferon therapy is safe and effective for nonresectable biliary tract adenocarcinoma.
    Hepatology international, 2015, Volume: 9, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2015
Capsaicin Enhances the Drug Sensitivity of Cholangiocarcinoma through the Inhibition of Chemotherapeutic-Induced Autophagy.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy

2015
Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification.
    The oncologist, 2015, Volume: 20, Issue:6

    Topics: Adult; Aged; Chemoembolization, Therapeutic; Cholangiocarcinoma; Enbucrilate; Epirubicin; Female; Fl

2015
Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
    International journal of oncology, 2015, Volume: 47, Issue:1

    Topics: Bile Duct Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Deoxycytidi

2015
Targeting the ∆133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells.
    International journal of oncology, 2015, Volume: 47, Issue:6

    Topics: Aged; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Cell Line, Tumor; Ce

2015
TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Caspases; Cell Line,

2015
A case of hepatoblastoma misdiagnosed as combined hepatocellular carcinoma and cholangiocarcinoma in an adult.
    Clinical and molecular hepatology, 2015, Volume: 21, Issue:3

    Topics: Adult; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Diagnostic Errors; Doxorubicin; Dru

2015
Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.
    PloS one, 2015, Volume: 10, Issue:11

    Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Anilides; Animals; Antineoplastic Combined Chemot

2015
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
    Cancer, 2016, Mar-01, Volume: 122, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2016
Targeted delivery of 5-fluorouracil to cholangiocarcinoma cells using folic acid as a targeting agent.
    Materials science & engineering. C, Materials for biological applications, 2016, Volume: 60

    Topics: Apoptosis; Cell Line, Tumor; Cholangiocarcinoma; Fluorouracil; Folic Acid; Humans; Nanomedicine; Nan

2016
Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells.
    Oncology research, 2016, 01-21, Volume: 23, Issue:1-2

    Topics: Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Benzamides; Bile Duct Neoplasms

2016
Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma.
    Gut and liver, 2016, May-23, Volume: 10, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cispl

2016
Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.
    Digestion, 2016, Volume: 93, Issue:3

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ca

2016
Upregulation of retinoic acid receptor-β reverses drug resistance in cholangiocarcinoma cells by enhancing susceptibility to apoptosis.
    Molecular medicine reports, 2016, Volume: 14, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Bile Ducts; Cell Line, Tum

2016
[Efficacy of Combined Therapy(Drainage of the Bile Duct, High-Dose Hepatic Artery Infusion, and Radiation)for Hilar Cholangiocellularcarcinoma with Complete Portal Vein Obstruction].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemoradiotherapy; Cholangiocarcinoma; D

2016
Characterization of 5-fluorouracil-resistant cholangiocarcinoma cell lines.
    Chemotherapy, 2008, Volume: 54, Issue:5

    Topics: Cell Line, Tumor; Cholangiocarcinoma; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regul

2008
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.
    International journal of radiation oncology, biology, physics, 2009, Jan-01, Volume: 73, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cholangiocarcinom

2009
[A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:12

    Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chola

2008
Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells.
    Liver international : official journal of the International Association for the Study of the Liver, 2009, Volume: 29, Issue:5

    Topics: Animals; Anticarcinogenic Agents; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Camellia sinens

2009
Oncolytic gene therapy combined with double suicide genes for human bile duct cancer in nude mouse models.
    The Journal of surgical research, 2009, Volume: 157, Issue:1

    Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Bile Duct Neoplasms; Bile

2009
Impact of rhenium-188, gemcitabine, and 5-fluorouracil on cholangiocellular carcinoma cells: an in vitro study.
    Cardiovascular and interventional radiology, 2009, Volume: 32, Issue:4

    Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Cell Cycle; Cholangiocarcinoma; Deoxycytidine

2009
[A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2009
Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma.
    Zeitschrift fur Gastroenterologie, 2010, Volume: 48, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile D

2010
Time to move to targeted drugs in biliary tract cancer?
    Onkologie, 2010, Volume: 33, Issue:1-2

    Topics: Adenocarcinoma; Ampulla of Vater; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo

2010
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
    Onkologie, 2010, Volume: 33, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2010
Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics.
    Journal of translational medicine, 2010, Mar-25, Volume: 8

    Topics: Abdominal Neoplasms; Animals; Antimetabolites, Antineoplastic; Area Under Curve; Cholangiocarcinoma;

2010
Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma.
    World journal of gastroenterology, 2010, Apr-07, Volume: 16, Issue:13

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Cell Line

2010
Long-term culture following ES-like gene-induced reprogramming elicits an aggressive phenotype in mutated cholangiocellular carcinoma cells.
    Biochemical and biophysical research communications, 2010, Apr-30, Volume: 395, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Cultur

2010
Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla

2010
Fatal immune haemolysis due to antibodies to individual metabolites of 5-fluorouracil.
    Transfusion medicine (Oxford, England), 2010, Aug-01, Volume: 20, Issue:4

    Topics: Anemia; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro

2010
Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents.
    Laboratory investigation; a journal of technical methods and pathology, 2010, Volume: 90, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cholangiocarcinoma; Cytochrome P-450

2010
Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro.
    BMC complementary and alternative medicine, 2010, Sep-28, Volume: 10

    Topics: Antineoplastic Agents, Phytogenic; Atractylodes; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholan

2010
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
    The journal of medical investigation : JMI, 2011, Volume: 58, Issue:1-2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell

2011
Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines.
    Asian Pacific journal of cancer prevention : APJCP, 2011, Volume: 12, Issue:1

    Topics: Antigens, CD; Antineoplastic Agents; Artemisinins; ATP Binding Cassette Transporter, Subfamily B; AT

2011
COP35, a cholangiocarcinoma-binding oligopeptide, interacts with the clathrin heavy chain accompanied by GRP78.
    Molecular cancer research : MCR, 2011, Volume: 9, Issue:6

    Topics: Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocar

2011
Neoadjuvant therapy protocol and liver transplantation in combination with pancreatoduodenectomy for the treatment of hilar cholangiocarcinoma occurring in a case of primary sclerosing cholangitis: case report with a more than 8-year disease-free survival
    Transplantation proceedings, 2011, Volume: 43, Issue:4

    Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Brachytherapy; Chemo

2011
Adjuvant radio-chemotherapy for extrahepatic biliary tract cancers.
    BMC cancer, 2011, Jun-24, Volume: 11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic;

2011
Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma.
    Anticancer research, 2011, Volume: 31, Issue:10

    Topics: Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycyti

2011
[Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2011, Volume: 108, Issue:11

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2011
Acute inflammatory demyelinating polyradiculoneuropathy in a patient receiving oxaliplatin-based chemotherapy.
    Asia-Pacific journal of clinical oncology, 2012, Volume: 8, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Fluorouraci

2012
Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
    Chemotherapy, 2012, Volume: 58, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah

2012
Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Chemotherapy, 2012, Volume: 58, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Bi

2012
Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil.
    World journal of gastroenterology, 2012, Aug-14, Volume: 18, Issue:30

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Su

2012
Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Journal of gastrointestinal and liver diseases : JGLD, 2012, Volume: 21, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms;

2012
Novel multimodality treatment sequencing for extrahepatic (mid and distal) cholangiocarcinoma.
    Annals of surgical oncology, 2013, Volume: 20, Issue:4

    Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Brachytherapy; Chola

2013
Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.
    The oncologist, 2012, Volume: 17, Issue:12

    Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers

2012
[Combination therapy for inoperable cholangiocellular carcinoma-systemic chemotherapy and hepatic arterial injection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chola

2012
[Two long-term survival cases of unresectable intrahepatic cholangiocarcinoma treated with hepatic arterial infusion chemotherapy and radiation therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic;

2012
Challenge in differential diagnosis of a liver mass histologically defined as a metastatic lesion from an occult primary intestinal tumour. The importance of clinical findings and the limitations of histology and molecular profiles. A case report.
    Pathologica, 2012, Volume: 104, Issue:4

    Topics: Adenoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intr

2012
Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2002, Volume: 2, Issue:8

    Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarc

2002
Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2002, Volume: 2, Issue:8

    Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarc

2002
Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2002, Volume: 2, Issue:8

    Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarc

2002
Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma.
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2002, Volume: 2, Issue:8

    Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarc

2002
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Cancer, 2004, Aug-01, Volume: 101, Issue:3

    Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato

2004
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Cancer, 2004, Aug-01, Volume: 101, Issue:3

    Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato

2004
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Cancer, 2004, Aug-01, Volume: 101, Issue:3

    Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato

2004
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Cancer, 2004, Aug-01, Volume: 101, Issue:3

    Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato

2004
Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2004, Volume: 36, Issue:9

    Topics: Antigens, Neoplasm; Bile Ducts, Extrahepatic; Biliary Tract Neoplasms; Biomarkers, Tumor; CA-19-9 An

2004
Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy.
    The American surgeon, 2004, Volume: 70, Issue:9

    Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy,

2004
[Successful treatment for advanced cholangiocellular carcinoma with intrahepatic metastasis and/or portal vein tumor thrombi by intraarterial chemotherapy combined with 5-fluorouracil, adriamycin and cisplatin (FAP)--two cases report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic;

2004
Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
    Cancer, 2005, Apr-01, Volume: 103, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chola

2005
[The evaluation of chemoradiotherapy to unresectable hepatobiliary cancers].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Combined Modalit

2005
[A case of unresectable cholangiocellular carcinoma treated with surgery followed by combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2005
Rapid resolution of liver metastasis from cholangiocarcinoma after bevacizumab with cisplatin and high-dose fluorouracil plus leucovorin.
    Onkologie, 2006, Volume: 29, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2006
Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways.
    Journal of hepatology, 2007, Volume: 46, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfami

2007
[A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bone

2006
[A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:12

    Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts,

2006
Effects of the anti-epidermal growth factor receptor antibody cetuximab on cholangiocarcinoma of the liver.
    Onkologie, 2007, Volume: 30, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2007
Unexpected response to systemic chemotherapy in case of primarily nonresectable advanced disseminated intrahepatic cholangiocarcinoma.
    World journal of surgical oncology, 2007, Mar-21, Volume: 5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic

2007
Effects of targeting magnetic drug nanoparticles on human cholangiocarcinoma xenografts in nude mice.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2007, Volume: 6, Issue:3

    Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Fluorouracil; Humans; Ma

2007
[A case of successful management of advanced cholangiocellular carcinoma by repeated hepatic resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocel

1996
Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo.
    Cancer research, 1997, Oct-01, Volume: 57, Issue:19

    Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepati

1997
[The study of continuous infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with primary liver cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cholangiocarcinoma;

1997
Long-term survival of a young woman with peripheral cholangiocarcinoma: a case report.
    Journal of clinical gastroenterology, 1999, Volume: 28, Issue:1

    Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy,

1999
[A case report: successful resection of advanced intrahepatic cholangiocarcinoma responding to preoperative hepatic artery infusion of 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma;

1999
Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma.
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2000, Volume: 6, Issue:3

    Topics: Antimetabolites, Antineoplastic; Brachytherapy; Cholangiocarcinoma; Disease Progression; Disease-Fre

2000
Palliation of unresectable hilar cholangiocarcinoma.
    Journal of surgical oncology, 2000, Volume: 75, Issue:2

    Topics: Antimetabolites, Antineoplastic; Cholangiocarcinoma; Fluorouracil; Humans; Liver Neoplasms; Palliati

2000
Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma--initial experience.
    European journal of radiology, 2002, Volume: 41, Issue:1

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2002
Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer.
    Archives of surgery (Chicago, Ill. : 1960), 2002, Volume: 137, Issue:1

    Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Fe

2002
[Conformal therapy of locally advanced cholangiocarcinoma of the main bile ducts].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2002, Volume: 6, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth

2002
Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases.
    Onkologie, 2002, Volume: 25, Issue:2

    Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine

2002
Limitations of conventional doses of chemoradiation for unresectable biliary cancer.
    International journal of radiation oncology, biology, physics, 2002, Jul-15, Volume: 53, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, In

2002